TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
40.37
+4.27 (11.83%)
May 6, 2026, 2:10 PM EDT - Market open
TG Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover TG Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $51.8, which forecasts a 28.31% increase in the stock price over the next year. The lowest target is $39 and the highest is $70.
Price Target: $51.8 (+28.31%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TG Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $70 | Strong Buy | Maintains | $60 → $70 | +73.40% | May 6, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $49 → $46 | Buy | Maintains | $49 → $46 | +13.95% | Feb 2, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $37 → $39 | Hold | Maintains | $37 → $39 | -3.39% | Jan 15, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $46 → $49 | Buy | Maintains | $46 → $49 | +21.38% | Nov 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +48.63% | Oct 6, 2025 |
Financial Forecast
Revenue This Year
924.14M
from 616.29M
Increased by 49.95%
Revenue Next Year
1.23B
from 924.14M
Increased by 33.20%
EPS This Year
1.47
from 2.77
Decreased by -46.87%
EPS Next Year
2.26
from 1.47
Increased by 53.28%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 987.0M | 1.7B | ||||||
| Avg | 924.1M | 1.2B | ||||||
| Low | 870.0M | 997.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 60.2% | 81.8% | ||||||
| Avg | 50.0% | 33.2% | ||||||
| Low | 41.2% | 7.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.70 | 3.24 | |||
| Avg | 1.47 | 2.26 | |||
| Low | 0.92 | 1.57 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -38.6% | 120.5% | |||
| Avg | -46.9% | 53.3% | |||
| Low | -66.7% | 6.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.